IRGM AND PRECISION AUTOPHAGY CONTROLS FOR ANTIMICROBIAL AND INFLAMMATORY DISEASE STATES AND METHODS OF DETECTION OF AUTOPHAGY

    公开(公告)号:US20180236024A1

    公开(公告)日:2018-08-23

    申请号:US15553786

    申请日:2016-02-25

    Applicant: STC.UNM

    Abstract: The present invention relates to the discovery that IRGM, encoded by a uniquely human gene which confers risk for inflammatory diseases, affects autoophagy through a hitherto unknown mechanism. The present invention shows that IRGM controls autophagy and that IRGM modulators, in particular, double-stranded RNA, including poly I:C, poly-UG (polyUGUGU) and polyl-CLC and muramyldipeptide and related analogs of same, including N-acetyl muramyl-L-alanyl-D-isoglutamine (DMP) and numerous other compounds as identified herein, which may be used alone, in combination, or in combination with alternative autophagy modulators and additional bioactive agents to provide effective therapies for a number of diseases, including cancer, bacterial infections and inflammatory diseases, especially including tuberculosis infections and Crohn's disease, among others. The present invention is also directed to compositions and methods for treating inflammatory or autophagy-related diseases including diseases which cause excessive inflammation in patients.

    Polony sequencing methods
    207.
    发明授权

    公开(公告)号:US09982296B2

    公开(公告)日:2018-05-29

    申请号:US14870513

    申请日:2015-09-30

    Applicant: STC.UNM

    Inventor: Jeremy Edwards

    Abstract: We describe ultra-high throughput polony genome sequencing that can permit, for example, generating raw data to re-sequencing the human genome in about one week (including library prep and sequencing) at a reasonable cost. The methods described herein include one or more of the following: (1) increasing polony sequencing read length, (2) improving library construction and emulsions protocols, (3) increasing bead density and/or moving to alternative clonal amplication strategies (other than emulsion PCR or ePCR), (4) extending software capabilities to allow SNP calls from our new sequencing raw data, (5) Dual Primer Emulsion PCR, and (6) diagnostic method exploiting one or more of the foregoing.

    Cell-based composite materials with programmed structures and functions

    公开(公告)号:US09970000B2

    公开(公告)日:2018-05-15

    申请号:US14996048

    申请日:2016-01-14

    CPC classification number: G01N1/2806 C08K3/36 C12N11/14 G01N1/2853

    Abstract: The present invention is directed to the use of silicic acid to transform biological materials, including cellular architecture into inorganic materials to provide biocomposites (nanomaterials) with stabilized structure and function. In the present invention, there has been discovered a means to stabilize the structure and function of biological materials, including cells, biomolecules, peptides, proteins (especially including enzymes), lipids, lipid vesicles, polysaccharides, cytoskeletal filaments, tissue and organs with silicic acid such that these materials may be used as biocomposites. In many instances, these materials retain their original biological activity and may be used in harsh conditions which would otherwise destroy the integrity of the biological material. In certain instances, these biomaterials may be storage stable for long periods of time and reconstituted after storage to return the biological material back to its original form. In addition, by exposing an entire cell to form CSCs, the CSCs may function to provide a unique system to study enzymes or a cascade of enzymes which are otherwise unavailable.

Patent Agency Ranking